Former FDA Chief Peter Marks Joins Eli Lilly to Lead Infectious Diseases Division
Peter Marks, the former director of the US FDA's Center for Biologics Evaluation and Research, has joined Eli Lilly (NYSE:LLY) as Senior Vice President, Molecular Discovery and Head of Infectious Diseases. His appointment comes after his resignation from the FDA in March 2023, reportedly due to pressure from US Health Secretary Robert F. Kennedy Jr.
Marks, who served as deputy director and later director of the FDA's CBER from 2012 to 2023, played a significant role in establishing Operation Warp Speed. This federal program was instrumental in accelerating the development of COVID-19 vaccines. In his resignation letter, Marks cited Secretary Kennedy's views on vaccines as a key factor in his decision to leave the FDA.
Eli Lilly, a leading global pharmaceutical company, has not yet officially confirmed Marks' hiring. However, industry sources have reported that Marks will be taking on a senior role within the company's molecular discovery and infectious diseases divisions.
Peter Marks' appointment at Eli Lilly signals a significant addition to the company's leadership team. His extensive experience in regulatory affairs and infectious diseases is expected to contribute to the company's ongoing efforts in developing innovative therapies. Despite Eli Lilly's yet-to-be-confirmed announcement, industry insiders anticipate Marks' role to be pivotal in driving the company's molecular discovery and infectious diseases initiatives.
Read also:
- Americans Lose Insurance Under New Tax Legislation, Affecting 10 Million Citizens
- Pro-Life Group Condemns FDA's Approval of Generic Abortion Drug
- Trump Signs Law Defunding Planned Parenthood, Threatening Healthcare Access for Millions
- Historian Ute Frevert Explores Germans' Emotional Bond With Constitutions
